Skip to main content
Premium Trial:

Request an Annual Quote

Applied Biosystems Reports Increased Revenues, Income for Q2 of FY2004

NEW YORK, Jan. 28 (GenomeWeb News) - Applied Biosystems reported increased revenues and earnings for its fiscal year 2004 second quarter, along with slightly increased R&D spending.


For the ending Dec. 31, 2003, Applied Biosystems reported revenues of $458.4 million, compared to $444.7 million for the same period a year ago.


Revenues in different product categories were as follows (year-ago revenues in brackets): DNA sequencing $170.4 million ($174.8 million), SDS and other applied genomics $104.3 million ($85.4 million), mass spectrometry $103.4 million ($92.6 million), revenues, core DNA synthesis and PCR $51.3 million ($51.9), other product lines $29 million ($40 million).


The company's net income for the quarter was $52.4 million, or $0.25 per share, compared to $29.2 million, or $0.14 per share, in the prior year quarter.


Applied Biosystems spent $60.7 million for R&D and engineering during the quarter, compared to $59.2 million the year before.


The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.